The influence of optimal medical treatment on the 'obesity paradox', body mass index and long-term mortality in patients treated with percutaneous coronary intervention: A prospective cohort study

BMJ Open

Volumn 2, Issue 1, 2012, Pages

  Schenkeveld, Lisanne ^a   Magro, Michael ^a   Oemrawsingh, Rohit M ^a,b   Lenzen, Mattie ^a   De Jaegere, Peter ^a   Van Geuns, Robert Jan ^a   Serruys, Patrick W ^a   Van Domburg, Ron T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; BARE METAL STENT; BODY MASS; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG ELUTING STENT; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

EID: 84857831561     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000535     Document Type: Article

References (27)

1. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year followup of participants in the Framingham Heart Study. Circulation 1983;67:968-77. (Pubitemid 13080473)
2. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105. (Pubitemid 29466221)
3. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925-32.
4. Galal W, van Gestel YR, Hoeks SE, et al. The obesity paradox in patients with peripheral arterial disease. Chest 2008;134:925-30.
5. Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007;120:863-70. (Pubitemid 47451305)
6. Byrne J, Spence MS, Fretz E, et al. Body mass index, periprocedural bleeding, and outcome following percutaneous coronary intervention (from the British Columbia Cardiac Registry). Am J Cardiol 2009;103:507-11.
7. Ellis SG, Elliott J, Horrigan M, et al. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol 1996;78:642-6. (Pubitemid 126658617)
8. Gurm HS, Brennan DM, Booth J, et al. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol 2002;90:42-5. (Pubitemid 34671201)
9. Minutello RM, Chou ET, Hong MK, et al. Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry). Am J Cardiol 2004;93:1229-32. (Pubitemid 38595675)
10. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578-84. (Pubitemid 34158151)
11. Gurm HS, Whitlow PL, Kip KE. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol 2002;39:834-40. (Pubitemid 34185331)
12. Powell BD, Lennon RJ, Lerman A, et al. Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 2003;91:472-6. (Pubitemid 36183574)
13. Hastie CE, Padmanabhan S, Slack R, et al. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J 2010;31:222-6.
14. Sarno G, Raber L, Onuma Y, et al. Impact of body mass index on the Five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents. Am J Cardiol 2011;108:195-201.
15. Steinberg BA, Cannon CP, Hernandez AF, et al. Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. Am J Cardiol 2007;100:1331-5. (Pubitemid 47576007)
16. van Kuijk JP, Flu WJ, Galal W, et al. The influence of polyvascular disease on the obesity paradox in vascular surgery patients. J Vasc Surg 2011;53:399-406.
17. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-5. (Pubitemid 38114138)
18. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxelversus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-41. (Pubitemid 40432449)
19. Anon. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and treatment of overweight in adults. Am J Clin Nutr 1998;68:899-917.
20. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused Updates: aCC/AHA guidelines for the Management of patients with STElevation myocardial infarction (updating the 2004 guideline and 2007 focused Update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused Update): a report of the American College of Cardiology Foundation/American heart association Task Force on Practice guidelines. Circulation 2009;120:2271-306.
21. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368:666-78. (Pubitemid 44223694)
22. McCarty MF. A paradox resolved: the postprandial model of insulin resistance explains why gynoid adiposity appears to be protective. Med Hypotheses 2003;61:173-6. (Pubitemid 36976176)
23. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40. (Pubitemid 37485568)
24. Kim S, Popkin BM. Commentary: understanding the epidemiology of overweight and obesityea real global public health concern. Int J Epidemiol 2006;35:60-7; discussion 81-2. (Pubitemid 43205444)
25. Gelber RP, Kurth T, Manson JE, et al. Body mass index and mortality in men: evaluating the shape of the association. Int J Obes (Lond) 2007;31:1240-7. (Pubitemid 47179723)
26. Allison DB, Faith MS, Heo M, et al. Hypothesis concerning the U-shaped relation between body mass index and mortality. Am J Epidemiol 1997;146:339-49. (Pubitemid 27355570)
27. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients With stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8. (Pubitemid 37093919)